Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670225 | 0.78 | MAPT (0.49) | MAPTTP53MAPK1HTTATM | |
| SCHEMBL20504876 | 0.76 | CHEK1 (0.35) | ALDH1A1 | |
| SCHEMBL670091 | 0.75 | MAPT (0.52) | MAPTTP53MAPK1HTTATM | |
| SCHEMBL20939417 | 0.71 | PDE4A (0.44) | MAPTTP53MAPK1HTTATM | |
| SCHEMBL9037988 | 0.70 | LMNA (0.58) | MAPTTP53HTTCNR2TSHR | |
| SCHEMBL20939414 | 0.69 | MAP3K14 (0.42) | SIGMAR1NPC1 | |
| SCHEMBL22434861 | 0.68 | HSD11B1 (0.36) | HTTTSHRL3MBTL1ALDH1A1 | |
| SCHEMBL30641089 | 0.67 | MAPK1 (0.49) | MAPTMAPK1TSHRLMNACREBBP | |
| SCHEMBL30641076 | 0.67 | TSHR (0.48) | MAPTTP53CNR2TSHRLMNA | |
| SCHEMBL20939721 | 0.66 | MAPT (0.42) | MAPTTP53MAPK1HTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2606032-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | University Of Washington Through Its Center For Commercialization (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | MGMT, NEFM, TP53 | MAPT 269/4885TP53 3/4885MAPK1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.